Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANTXR2 | P58335 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 10/20 | 0.39 |
| ▸ | CA12 | O43570 | 9/20 | 0.39 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23651803 | 1.00 | ANTXR2 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL29774502 | 1.00 | ANTXR2 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL29525898 | 1.00 | ANTXR2 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL5533141 | 0.94 | CYP2D6 (0.47) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL29466752 | 0.94 | CYP2D6 (0.47) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL270320 | 0.93 | CYP2D6 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL17775913 | 0.93 | CYP2D6 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL24105675 | 0.93 | CYP2D6 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL23651823 | 0.93 | CYP2D6 (0.46) | ANTXR2CYP2D6THRBHSD17B10CA2 | |
| SCHEMBL17326907 | 0.93 | CYP2D6 (0.44) | ANTXR2CYP2D6THRBHSD17B10CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151453-A1 | Drug/polymer Composite Materials And Methods Of Making The Same | MICELL TECHNOLOGIES, INC. (US) | 2019-05-23 | — | — | US | claimed |
| EP-1898878-A2 | DRUG/POLYMER COMPOSITE MATERIALS AND METHODS OF MAKING THE SAME | Micell Technologies, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1796653-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20070009564-A1 | Drug/polymer composite materials and methods of making the same | MICELL SPV I LLC | 2007-01-11 | — | — | US | claimed |
| WO-2007002238-A2 | DRUG/POLYMER COMPOSITE MATERIALS AND METHODS OF MAKING THE SAME | MICELL TECHNOLOGIES INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | COTHERIX, INC. | 2006-07-06 | — | — | US | claimed |
| WO-2006014930-A2 | TREATMENT OF PULMONARY HYPERTENSION BY INHALED ILOPROST WITH A MICROPARTICLE FORMULATION | COTHERIX, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-6586006-B2 | Vitreous vehicle loaded with guest substance such as drugs, enzymes, vaccines; vehicle allows guest substance to be dried and stored without loss of activity | ELAN DRUG DELIVERY LIMITED (GB) | 2003-07-01 | — | — | US | claimed |
| EP-0949907-B1 | METHODS AND COMPOSITIONS FOR IMPROVED BIOAVAILABILITY OF BIOACTIVE AGENTS FOR MUCOSAL DELIVERY | ELAN DRUG DELIVERY LTD (GB) | 2003-03-19 | — | — | EP | claimed |
| US-6517860-B1 | Powder of drug and hydrophobically derivatized carbohydrate; efficacy | QUADRANT HOLDINGS CAMBRIDGE, LTD. (GB) | 2003-02-11 | — | — | US | claimed |
| US-20010038858-A1 | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same | QUADRANT DRUG DELIVERY LIMITED (GB) | 2001-11-08 | — | — | US | claimed |
| EP-0949907-A1 | METHODS AND COMPOSITIONS FOR IMPROVED BIOAVAILABILITY OF BIOACTIVE AGENTS FOR MUCOSAL DELIVERY | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1999-10-20 | — | — | EP | claimed |
| WO-1998029097-A1 | METHODS AND COMPOSITIONS FOR IMPROVED BIOAVAILABILITY OF BIOACTIVE AGENTS FOR MUCOSAL DELIVERY | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1998-07-09 | — | — | WO | claimed |
| EP-0773781-A1 | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1997-05-21 | — | — | EP | claimed |
| WO-1996003978-A1 | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1996-02-15 | — | — | WO | claimed |
| US-20190151453-A1 | Drug/polymer Composite Materials And Methods Of Making The Same | MICELL TECHNOLOGIES, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-1556134-B1 | TRANSDERMAL DELIVERY SYSTEM FOR DRIED PARTICULATE MEDICATIONS | SYNERON MEDICAL LTD (IL) | 2015-08-26 | — | — | EP | disclosed |
| WO-2001003673-A1 | DRY POWDER COMPOSITIONS | QUADRANT HEALTHCARE (UK) LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-0773781-A1 | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003978-A1 | SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME | QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038858-A1 | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same | MMP1, STRA6, PGF | ANTXR2 1819/4885CYP2D6 1259/4885THRB 2364/4885 |
| US-20060147520-A1 | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | PTGIR, PTGIS, PTGER1 | ANTXR2 4485/4885CYP2D6 912/4885THRB 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.